The BGC reader is gym-adjacent in a way no other district in the metro is. Fitness and aesthetics are the local culture, the buyer usually already runs some kind of tracked training, and they arrive at retatrutide having already been through semaglutide or tirzepatide either personally or through somebody at their gym. What they want is not a weight number. It is a body composition answer.
I will be straight about the limits of what I can tell them, because this is where BGC gets fed the most confident nonsense. The published Phase 2 data is a body-weight endpoint. It is not a lean mass endpoint, and body weight includes lean mass. Anyone quoting you a partitioning figure for retatrutide, whether that is a coach on a gym floor in Uptown or a supplier trying to close a sale, is going beyond what has been published.
What is genuinely distinctive about the molecule is on the compound page and worth reading there rather than being paraphrased through three people. It is a triple agonist. Alongside the GLP-1 and GIP receptors that tirzepatide already hits, it activates the glucagon receptor, and glucagon agonism is what the mechanism literature associates with increased metabolic rate and fat oxidation. That is a mechanism description, not a promise about your physique.